Abstract:Background: A systematic search was performed on the Web of Science, PubMed, Embase, and Cochrane databases. The meta-analysis was performed to evaluate the effect of epidermal growth factor receptor (EGFR) mutation status on programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors, and the association between EGFR mutation status and PD-L1 expression in non-small cell lung cancer (NSCLC) patients.Methods: Pooled effect (HR/OR) with 95% CI was calculated, the source of heterogeneity was explored by subgroup analysis and meta-regression using Stata/SE 15.0. Meta-analysis of the association between EGFR mutation status and overall survival in NSCLC with immunotherapy was calculated from four randomized controlled trials. Results: We found that immune checkpoint inhibitors significantly prolonged overall survival (OS) over docetaxel overall (HR: 0.71, 95% CI: 0.64-0.79) and in the EGFR wild-type (HR=0.67, 95% CI=0.60-0.75), but not in the EGFR-mutant subgroup (HR=1.11, 95% CI=0.80-1.52). Meta-analysis of the association between EGFR mutation status and PD-L1 expression in NSCLC included 32 studies. The pooled OR and 95% CI were 0.60 (0.46 0.80), calculated by random effects model. No source of heterogeneity was found in subgroup analysis. The sensitivity analysis was carried out with a fixed model, and the influence of a single study on the pooled results showed no significant change with robust meta-analysis methods. Harbord s weighted linear regression test (P=0.956) and Peters regression test (P=0.489) indicated no significant publication bias. Conclusions: The benefit of PD-1/PD-L1 immune checkpoint inhibitor treatment in patients with EGFR-mutated NSCLC is not obvious and may due to the lower expression of PD-L1.Funding: This study was supported by Fujian Program for Outstanding Young Researchers in University awarded by Education Department of Fujian (Grant Number 2017B019), Fujian Provincial Health Research Talents Training Programme Medical Innovation Project (Grant Number 2019- CX-33), Joint Funds for the innovation of science and Technology，Fujian province (Grant Number 2019Y9022), and Fujian Provincial Health Research Talents Training Programme Youth Research Project (Grant Number 2019-1- 58).The funding sponsors played no role in study design, data collection, data analysis, interpretation, writing of the report, and the decision to submit the paper for publication.Declaration of Interest: None to declare. Ethical Approval: This study was approved by the Institutional Review Board of Fujian Medical University (Fuzhou, China).

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation

PD-1/PD-L1 Pathway in Non-Small Cell Lung Cancer and Its Relation with Epidermal Growth Factor Receptor Mutation

Progress in PD-1/PD-L1 inhibitors combined with other approaches in the treatment of non-small cell lung cancer

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

Progress in the Study on PD-L1 Inhibitor in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer

[Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

The Association Between PD-L1 and EGFR Status and the Prognostic Value of PD-L1 in Advanced Non-Small Cell Lung Cancer Patients Treated with EGFR-TKIs

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Progress on the Study of PD-L1 Detection Methods in Non-small Cell Lung Cancer

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer

PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.

Advances of the relationship between PD-1/PD-L1 pathway and KRAS gene mutation in non-small cell lung cancer

Molecular Mechanism of Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma

PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Association Between EGFR Mutation Status and Immune Checkpoint Inhibitors and PD-L1 Expression in Non-Small-Cell Lung Cancer: A Meta-Analysis